anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Upon initial screening and again within a week of testing, all subjects will have an assessment of 24-hour ambulatory blood pressure. Subject screening will be performed by the Penn State Clinical Translational Research Center (CTRC) medical staff and will include a physical exam by a clinician, anthropometry, and a chemical and lipid profile, liver and renal function. Women will be either postmenopausal (absence of menstruation of \>1 year and Follicle Stimulating Hormone (FSH) \>25 milli-international units per milliliter (mlU/ml)) and not be taking hormone replacement therapy, or normally menstruating and tested in the early follicular phase of their cycle. Subjects will also go through an assessment of conduit vessel endothelial and vascular smooth muscle function with brachial artery flow-mediated vasodilation (FMD), and sublingual nitroglycerin.

Subjects will undergo initial microdialysis experiments and biopsy samples will be obtained. Subjects will then be randomly assigned to treatment group. Blood pressure will be monitored every 2 weeks and weekly compliance checks will be made by the researcher's nurse coordinator. 24-hour ambulatory blood pressure monitoring will be conducted monthly to determine the efficacy of antihypertensive treatment and to inform dosing titration. Examining pharmacokinetic and dynamic data from the literature indicate that blood pressure lowing and peripheral vascular effects are maximized by 12 weeks of antihypertensive therapy and maintained thereafter. After 16 weeks of the assigned intervention, subjects will repeat microdialysis experiments and additional cutaneous biopsy samples will be obtained. Conduit artery measures including brachial artery FMD and responsiveness to sublingual nitroglycerin will also be evaluated at this time.
BACKGROUND: Cervical cancer is one of the most common gynecological cancers. Accumulated evidence shows that long non-coding RNAs (lncRNAs) play essential roles in cervical cancer occurrence and progression, but their specific functions and mechanisms remain to be further explored.
METHODS: The RT-qPCR assay was used to detect the expression of NEAT1 in cervical cancer tissues and cell lines. CCK-8, colony formation, flow cytometry, western blotting, and Transwell assays were used to evaluate the impact of NEAT1 on the malignant behavior of cervical cancer cells. Glucose consumption, lactate production, ATP levels, ROS levels, MMP levels, and the mRNA expressions of glycolysis-related genes and tricarboxylic acid cycle-related genes were detected to analyze the effect of NEAT1 on metabolism reprograming in cervical cancer cells. The expressions of PDK1, β-catenin and downstream molecules of the WNT/β-catenin signaling pathway in cervical cancer cells and tissues were detected by western blotting, RT-qPCR, immunofluorescence and immunohistochemistry assays.
RESULTS: This study investigated the role and possible molecular mechanism of lncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) in cervical cancer. Our results showed that NEAT1 was highly expressed in cervical cancer tissues and cell lines. Downregulation of NEAT1 inhibited the proliferation, migration, invasion and glycolysis of cervical cancer cells, while overexpression of NEAT1 led to the opposite effects. Mechanistically, NEAT1 upregulated pyruvate dehydrogenase kinase (PDK1) through the WNT/β-catenin signaling pathway, which enhanced glycolysis and then facilitated cervical cancer metastasis. Furthermore, NEAT1 maintained the protein stability of β-catenin but did not affect its mRNA level. We also excluded the direct binding of NEAT1 to the β-catenin protein via RNA pull-down assay. The suppressive impact of NEAT1 knockdown on cell proliferation, invasion, and migration was rescued by β-catenin overexpression. The WNT inhibitor iCRT3 attenuated the carcinogenic effect induced by NEAT1 overexpression.
CONCLUSION: In summary, these findings indicated that NEAT1 may contribute to the progression of cervical cancer by activating the WNT/β-catenin/PDK1 signaling axis.
The invention discloses hydroxytyrosol eye drops for effectively targeting trigeminal ganglion and a preparation method thereof. The eye drops comprise hydroxytyrosol used as a main drug and a preservative, an isoosmotic adjusting agent, a polyethylenecaprolactam-polyvinyl acetate-polyethylene glycol copolymer and lidocaine or its pharmaceutically acceptable salts. Mass ratio of the hydroxytyrosol main drug to the polyethylenecaprolactam-polyvinyl acetate-polyethylene glycol copolymer drug excipient is 1: 18. Mass ratio of lidocaine to the polyethylenecaprolactam-polyvinyl acetate-polyethylene glycol copolymer drug excipient is 1: 18-1: 90. The eye drops of the invention have good solubility and stability, and micelles have controllable particle size, uniform distribution range and good storage stability. Through ocular surface administration, the eye drops effectively target and are absorbed by trigeminal ganglion, thus raising safety and effectiveness of the medicine in treating diabetic keratopathy and nervous lesion.
The patients without dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes "30 minutes sustained reading", a detailed dry eye exam will be performed.
A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by T max  at 4-10 hours and an approximately linear drop-off thereafter and C max  below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml. The composition allows milnacipran to be delivered over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.
The invention discloses a novel sustained-release transdermal medicament delivery system for treating ulcer and wound surface. The system contains an auxiliary material with a biological adhesion effect. The system is a dry gel preparation prepared by blending the auxiliary material and an active medicament and then performing freeze drying on the mixture. After being hydrated on the ulcer and the wound surface, the preparation tightly contacts the ulcer and the wound surface, so that the residence time of the medicament on the ulcer and the wound surface is obviously prolonged and the treatment effect of the medicament is fully brought into full play; at the same time, the preparation has good elasticity and flexibility, so that the preparation inosculates with the biological curve of the ulcer or the wound surface; and after being hydrated, the preparation is formed into a gel and the active medicament dispersed in the gel is slowly released onto an action part, so that the action time of the medicament is prolonged. At the same time, the gel formed after the medicament is hydrated plays a role in isolating and protecting the wound surface and can quicken the concrescence of the wound surface. The preparation is small and light, has no foreign body sensation and peculiar smell and is suitable for all patients.
FIELD: medicine. SUBSTANCE: method involves stimulating corporal and auricular biologically active points. Microelectrophoresis is applied to a number of corporal biologically active points. 0.5% solution of humic acid from sulfide mud of low mineral contents on isotonic solution of sodium chloride is used for this purpose. Electroacupuncture is applied for stimulating auricular and the rest of the corporal biologically active points. EFFECT: prolonged remission period.
A magnetic microparticle drug carrier comprising mesoporous iron oxide is described. The drug carrier has an average diameter in a range of 0.5-1.2 μm, a BET surface area ranging from 50-300 m 2 /g, and a pore volume ranging from 0.15-0.65 cm 3 /g. The drug carrier is made using a hard mesoporous silica template which is completely removed from the deposited iron oxide. The drug carrier may be loaded with high amounts of hydrophilic anticancer chemotherapeutic drugs and/or hydrophobic hormonal anticancer drugs, and released in a pH-controlled manner inside cancerous cells. Compared to free drugs, the drug microparticle carrier displays enhanced drug accumulation inside tumor tissues, deeply penetrates into a tumor region and kills the tumor cells inside. The designed carriers described here entrap and release different kinds of anticancer drugs in a controlled manner for synergistic combinatorial chemo/hormonal cancer therapy.
This is a randomized, double-blind, placebo-controlled clinical trial to investigate the anti-obesity effect of kimchi fermented with the addition of specific lactic acid bacteria.

Two different kimchi, one traditional kimchi and one fermented with a lactic acid bacteria having anti-obesity effect, hereafter starter kimchi, are flash freeze dried, powdered and encapsulated. Specifically, subjects with a BMI of between 23\~30kg/m2 take 1,200 mg of traditional kimchi or starter kimchi capsules three times per day before each meal, for a total of 3,600 mg per day. As a control, subjects with a BMI of 23 to 30 kg/m2 take lactose capsules in a similar form and in the same amount. The total study period is 16 weeks of intake of kimchi capsules or placebo capsules, excluding the 2 weeks of preparation period for subject selection. Before and after taking the kimchi capsule or the placebo capsule, the following evaluation criteria of the subject will be measured; DEXA (Dual Energy X-ray Absorptiometry), BMI, Weight, Waist to Hip ratio (WHR), total cholesterol, triglyceride, HDL-C, calculate LDL-C, FFA, HbA1c, glucose, insulin, HOMA-IR, hs-CRP, Adiponectin, Leptin. Also, Changes in gut microbiome composition will be determined by measuring bacterial population levels in stool samples collected before and after taking kimchi capsules or placebo capsules.
Obesity and asthma are global public health problems. Obesity-related asthma is a special phenotype of asthma with a complex pathogenesis. Its occurrence and development are related to mechanical compression, inflammatory response, metabolic regulation, gene regulation, and vitamin D deficiency. Different treatment strategies used in the process of weight loss have a beneficial impact on asthma. Alterations in gut and airway microbial community structure and their metabolites may also contribute to obesity-related asthma. The role of the Th17/Treg balance in the gut microbiota regulating the immune responses and host metabolism is important. Therapeutic measures associated with the gut microbiota variety may contribute to improving chronic inflammation associated with obesity by regulating the Th17/Treg balance. An early reduction in microbial diversity can predict the development of asthma and lead to allergy through an imbalance of Th2/Th1 responses. Short-chain fatty acids (SCFAs) regulate the differentiation and activation of regulatory T cells, thereby regulating immune homeostasis in the lung to suppress allergic inflammation and weight gain. Therefore, clarifying the microbial mechanism of obesity-related asthma has important guiding significance for clinical treatment. In this review, we used the following terms: "asthma and obesity" and "obesity-related asthma", combining "phenotype", "airway inflammation" and "lung function", and reviewed the characteristics and pathogenesis of obesity-related asthma, the relationship between the gut and airway microbiota and obesity-related asthma, and the current treatment measures for the disease.
The present invention relates to a composition for a lip paint based on the flower extract of Hibiscus Sabdariffa, which is the ingredient that establishes the difference concerning conventional lipsticks. Said composition possesses a formidable source of vitamin A, C, B1, and E, thus working against premature lips aging, being an antioxidant that protects them from free radicals and provides an immune and resistant system. Also, it comprises a high degree of niacin and riboflavin, vitamins that aids to maintain healthy skin. The composition is designed to possess greater durability once applied on lips, and long storage stability (1 year). Moreover, it is possible to achieve modern matte tones for any occasion, as well as working against the dry, rough skin and cracking of the lips caused by food, weather and even by the saliva itself. Finally, the present invention describes the obtaining method thereof.
The Alberta Project Promoting active Living and healthy Eating in Schools (APPLE Schools) is a quasi-experimental pre-post trial with a non-equivalent parallel control group. The intervention began in January 2008 and lasted through June 2011 and was implemented school-wide. As out primary interest is to reduce the prevalence of overweight and obesity in schools, the essential comparisons were across grade five students in differing calendar years. At each survey all grade five students were invited to participate. The current design allowed intervention effects to be assessed over time at the school-level. Surveys were administered in the spring of 2008, 2009, 2010, and 2011 in intervention schools. And in the spring of 2008 and 2011 in control schools.
According to an aspect, a pair of related entities that includes a first entity and a second entity is received. Distributional relations are detected between the first entity and the second entity. The detecting includes identifying two sets of entities in a corpus, the first set including the first entity and at least one other entity that is semantically similar to the first entity, and the second set including the second entity and at least one other entity that is semantically similar to the second entity. Semantic relations are detected between entities in the first set and entities in the second set. A relation classifier is trained using the pair of related entities and detected semantic relations. The relation classifier model is applied to a new pair of entities to determine a likelihood of a semantic relation between the entities in the new pair of entities.
To provide esomeprazole-containing granules having excellent handleability in preparing an oral formulation.SOLUTION: A granule is formed of a granular core part containing Esomeprazoles and a coating part coating the granular core part, in which the coating part prepares granules including an enteric layer and an outermost layer which coats the enteric layer and contains polyhydric alcohol fatty acid ester. It is preferable that the outermost layer does not substantially contain enteric polymer. The polyhydric alcohol fatty acid ester may be glycerol monostearate. The ratio of the polyhydric alcohol fatty acid ester may be 30 to 60 pts.mass for 100 pts.mass of the outermost layer. The outermost layer may further contain surfactant having oxyalkylene group. The outermost layer may further contain Hypromellose, and the ratio of the Hypromellose may be 10 to 60 pts.mass for 100 pts.mass of the outermost layer. The ratio of surfactant having the oxyalkylene group may be 1 to 30 pts.mass for 100 pts.mass of the polyhydric alcohol fatty acid ester.SELECTED DRAWING: None
Stable lipase prepd. by culturing a strain of Mucoraceae under aerobic conditions until the enzyme-activity of the medium has become constant; the mycelium is then separated from the liquid and the lipase removed from the filtrate. Lipase in general is an important enzyme in fat-metabolism by hydrolysis of triglycerides. The new lipase may be used in the therapy of gastrointestinal ailments caused by pancreas-insufficiency, insufficiency of secretion caused by age, atheromatoses and psoriasis, which is often accompanied by disturbances in the fat-metabolism. Specially purified prepns. may be used in the treatment of all forms of pancreas insufficiency, possibly accompanied by steatorrhea, dyspepsia, difficulties of fat-metabolism, fat intolerance, dyslepemias and difficulties in fat-absorption after operations of the metabolic system. The very pure form may be injected whereby the lipase is present in the form of a lyophilic-dried powder which is dissolved in situ in physiological salt soln. or suitable buffer. Therapeutic indications: Xanthomatoses, arteriosclerosis, severe pancreas-insufficiency, essential hyperlipidemia and inherent dyslipidemia. The known lipase is based on dried and powdered pancreas which has limited activity, is only active at pH 7.5-9.5, has great instability together with unpleasant odour and taste. The new lipase is very active, stable and free from unpleasant odour.
As part of the monitoring needed for this study, participants will be enrolled for at least 6 months, as this will give enough data to understand how the participant's health changes associate with what is measured by the Apple watch. After this 6 month period, participants may choose to end their participation on the study, or continue if they wish.
A method of treating or preventing restenosis by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient. The active ingredient effects restenosis by inhibiting the growth and proliferation of the cell types involved in the restenotic cascade, such as macrophages/monocytes, fibroblasts and smooth-muscle cells.
Telerehabilitation based exercises and vacuum bell therapy will be applied to this group. Video conference software system will be installed on the subjects' laptops or tablets. After the evaluations, exercises will be taught to the individuals in the clinic. Then, the following exercises will be done with the physiotherapist via video conference 3 sessions per week.
A uniform "intensive" 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms "INDOMETHACIN" and "6-MP/MTX" (mercaptopurine and Methotrexate).
An integrated hydrogen gas generator with hydrogen water module comprises a water tank, an electrolytic module, an integrated flow channel device, a humidifying module, and a hydrogen water module. The electrolytic module is configured to electrolyze the water in the water tank to generate a gas comprising hydrogen. The water tank, the humidifying module, and the hydrogen water module are respectively coupled to the integrated passageway module so that the water and the gas comprising hydrogen flow in a special sequence between them. The humidifying module is configured to humidify the gas comprising hydrogen. The hydrogen water module is configured for accommodating liquid and receiving the gas comprising hydrogen into the liquid to form a liquid comprising hydrogen. The configuration of pipeline is replaced by the integrated passageway module in the integrated hydrogen gas generator of the present invention.
Light has benefits in many pathologies, especially in psychiatry and sleep disorders. It is the most powerful Zeitgeber, allowing a drive of the sleep-wake rhythm. But what are the "doses or quantities" of light necessary for humans to stimulate circadian regulation? And how is it possible to promote better people's exposure to this amount of light during winter (especially in Nordic countries where daily light exposure during winter is particularly reduced: 8 hours on average)? At the Bispebjerg Hospital, following the installation of LED lighting, a dynamic system favoring a greater light intensity in blue wave color light in the morning and a gradual decrease in light intensity in the evening adjusted for geographical orientation of the patients' rooms is evaluated. This device was effective on anxious and depressive symptoms for patients hospitalized after a stroke. Here, we'll study the effect the light may have on patients in psychiatric closed wards. Moreover, we'll assess the users' satisfaction and the energy consumption of the system.

If the described intervention is associated with a reduction in the duration of stay of the patients in the ward as well as with a general satisfaction of the users and that it consumes much less energy, one could think of the installation of this system on a large scale not only in hospitals but also in schools or other public buildings where it could be interesting to have this adapted lighting.
The breast cancer resistance protein (ABCG2/BCRP) human transporter, encoded by the ABCG2 gene, is highly expressed on the human lactating breast. Nifedipine, a known substrate of ABCG2, is used for the treatment of hypertension in pregnancy and during breastfeeding. ABCG2 plays an important role on secreting drugs and xenobiotics into milk. The aim of the present study was to evaluate the effect of ABCG2 c.421C\>A on nifedipine breast milk/plasma concentration ratio in hypertensive breastfeeding women. Nineteen hypertensive breastfeeding women treated with 20 mg slow-release nifedipine every 12 hours were investigated. Blood and breast milk samples were collected simultaneously 15-30 days after delivery and at least 15 days after drug treatment, in order to reach drug steady state. All patients were genotyped for ABCG2 c.421C\>A using real time-PCR. Nifedipine concentration was determined in plasma and breast milk by high-performance liquid chromatography using UV detection. The comprehension of the variability in the transport of nifedipine to breast milk in hypertensive breastfeeding women will contribute to the evaluation of drug exposure in breast-fed infants to nifedipine and other ABCG2 substrates.